Phase 1 Alopecia Areata Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women between 18 and 70 years old, or men between 18 and 60 years old at the time of signing up for the trial
• People who have been diagnosed with Alopecia Areata (AA), including specific types called ophiasis, totalis, or universalis
• Women who could become pregnant must have a negative pregnancy test within 14 days before starting treatment
• Women who could become pregnant must agree to use a highly effective form of birth control before and for at least 28 days after the last dose of the study drug, and men must agree to use a barrier method (such as a condom) for the same period
• People whose recent blood test results (taken within 28 days of starting treatment) show that their blood cell counts, kidney function, and liver function are all within acceptable ranges (confirm with trial site)
• People who are able and willing to attend all required study visits and follow study procedures
• People who are able and willing to sign a consent form agreeing to take part in the study

Who may not be able to join:

• Women who are pregnant or breastfeeding, or anyone of reproductive age who is unwilling to use birth control
• People whose Alopecia Areata is mainly the "diffuse" type, which causes widespread general hair shedding across the scalp
• People who have another type of hair loss condition in addition to AA
• People who have previously used a medication called Aldesleukin or any experimental IL-2 (a type of immune system drug) similar to the study drug
• People currently using oral or topical treatments for hair growth or restoration (such as finasteride, dutasteride, or minoxidil) if they plan to stop or change the dose during the study
• People who have used light therapy, systemic immune-suppressing medications (such as steroids, cyclosporin, or methotrexate), or certain biologic medications (such as dupilumab) within the 3 months before screening
• People who have used certain B-cell depleting medications (such as rituximab) within the 6 months before screening
• People who have a known allergy or sensitivity to medications similar to the study drug
• People with a history of diabetes, whether controlled or not
• People who have had a heart attack, heart failure, uncontrolled irregular heartbeat, stroke, uncontrolled high blood pressure, or uncontrolled diabetes within the 6 months before screening
• People with serious, unstable, or poorly treated organ problems within the 6 months before screening
• People with a history of cancer or lymphoma, except for certain treated skin cancers with no current signs of disease
• People currently taking long-term antibiotic or antiviral medicines by mouth or through a drip for a chronic (ongoing) infection
• People with active tuberculosis (TB), or a history of TB that was not fully treated
• People who had a shingles (herpes zoster) or CMV infection that cleared up less than 2 months before screening, or people who get cold sores or herpes simplex outbreaks 4 or more times a year
• People who had major surgery within 3 months before screening, or who have major surgery planned during the study
• People with an active infection currently requiring antibiotic or antiviral treatment given through a drip
• People who have previously had an organ transplant
• People who test positive for HIV, hepatitis B, or hepatitis C at screening
• People still experiencing side effects from previous treatments that have not sufficiently cleared up
• People with mental health or personal circumstances that would make it difficult to follow the study's requirements
• People with other skin conditions that could interfere with how the study measures the effects of AA
• People with any other illness or medical issue that the study doctor believes would make participation unsafe or unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.